Major advances in antiepileptic drug therapy have taken place since 1950s. In the first period, several antiepileptic
drugs (AEDs) such as phenobarbital, diphenylhydantoin, ethosuximide, carbamazepine, benzodiazepines and valproic
acid were introduced to epilepsy treatment. After 1990 many new generation drugs (lamotrigine, topiramate, gabapentine,
pregabaline, felbamate, lacosamide, levetiracetam etc.) have been developed. These novel AEDs have offered
some advantages such as fewer side effects, fewer drug-drug interactions, and better pharmacokinetic properties. But
pharmacoresistance and therapeutic failure in 20-25% of the patients remain the main reasons to continue efforts to find
safer and more efficacious drugs and ultimate a treatment for this devastating disease. Several AEDs especially novel
compounds have been found to be effective also in the treatment of several other neurologic and psychiatric disorders.
Chemical diversity of the newer antiepileptic drugs as well as those currently in clinical development is another point that
encourages medicinal chemists to study this subject. This review summarizes recent studies on the development of potential
anticonvulsant compounds in different chemical structures, their structure-activity relationships and also therapeutic
usages of AEDs other than epilepsy.
Antiepileptic drug development strategies, anticonvulsant drug research, new anticonvulsant compounds, nonepileptic
uses of AEDs, QSAR
Hacettepe University, Faculty of Pharmacy, Pharmaceutical Chemistry Department, Ankara, Turkey.